A well-constructed DHF tells a coherent story: here is what the device was intended to do, here is how design requirements were established from those intentions, here is how the design was verified to meet its requirements, and here is how it was validated to meet user needs in actual use conditions. A poorly constructed DHF — one with missing records, broken traceability between requirements and verification results, or undefined design controls — tells a very different story, one that tends to generate multiple Form 483 observations and occasionally warning letters.

This guide covers what must go into a DHF, how to structure it, and the most common mistakes that lead FDA reviewers to question whether a company’s design process was genuinely controlled.

What FDA requires in a DHF

21 CFR 820.30(j) states that each manufacturer must establish and maintain a DHF for each type of device. The DHF must contain or reference the records necessary to demonstrate that the design was developed in accordance with the approved design plan and the requirements of the design controls regulation.

The QMSR, which aligns FDA requirements more closely with ISO 13485:2016, reinforces these requirements and adds explicit expectations around risk management integration throughout the design process. A DHF that satisfies current FDA expectations covers these core areas:

• Design and development planning records
• Design input records (user needs, intended use, requirements)
• Design output records (specifications, drawings, software documentation)
• Design review records
• Design verification records
• Design validation records
• Design transfer records
• Design change records
• Risk management file records (per ISO 14971)

Each of these categories represents a phase of the design process, and they must be traceable to each other. An FDA investigator should be able to pick up any design output and trace it back to the design input that generated it, and forward to the verification test that confirmed it was met.

DHF vs. Device Master Record vs. Device History Record

The DHF is frequently confused with two related regulatory concepts. Understanding the distinction matters because FDA treats them as separate records with separate purposes.

The DHF contains the evidence of the design process: the work done to design the device. The Device Master Record (DMR) contains the specifications and procedures needed to manufacture the device: drawings, manufacturing specifications, quality plans, and labeling. The Device History Record (DHR) contains the production records for each manufactured batch or unit: what was made, when, by whom, and whether it met specifications.

These three records form a connected triad. The DHF establishes that the design is sound. The DMR defines how to build it. The DHR proves that it was built correctly. For a 510(k) submission, FDA focuses on the DHF. During a manufacturing inspection, investigators examine all three.

Structuring the DHF for FDA review

There is no single format FDA mandates for the DHF, but the structure should make traceability easy to demonstrate. A DHF that requires an investigator to search through five separate filing locations to connect a design requirement to its verification evidence is a DHF that creates problems during inspections. The best-structured DHFs are organized either chronologically by design phase or by section, with a clear index and cross-referencing between records.

Design and development planning

The DHF should begin with the design and development plan, a document that establishes the overall approach to the design project: what is being designed, who is responsible for each activity, what the project milestones are, and how design reviews will be conducted. The plan does not need to predict every activity in advance, but it should be updated as the design evolves and reviewed during formal design reviews.

Design inputs

Design inputs are the requirements the device must meet. They come from multiple sources: clinical and user needs, applicable standards, regulatory requirements, business requirements, and risk analysis. FDA expects design inputs to be documented, reviewed, and approved by qualified personnel before design work begins in earnest.

The most common design input failure is vagueness. A design input that states “the device should be easy to use” is not a requirement that can be verified. A design input that states “the device must be operated with one hand by a user wearing standard surgical gloves with a grip force not exceeding 15 Newtons” is verifiable. FDA investigators who find design inputs written in broad, unverifiable language consistently question whether the design process was genuinely controlled.

Design outputs

Design outputs are the results of design work: engineering drawings, material specifications, software design documents, labeling specifications, and manufacturing instructions. Each design output must trace to one or more design inputs, and the DHF must make this traceability visible. A design traceability matrix, linking each design input to the outputs that satisfy it and the verification tests that confirm they do, is the most efficient way to demonstrate this to an FDA reviewer.

Design reviews

Formal design reviews must be conducted at appropriate stages of the design process. The DHF must contain records of each review: who attended, what was reviewed, what questions or issues were raised, and how those issues were resolved. Design reviews that are documented only as a brief sign-off with no record of the issues discussed do not satisfy FDA’s expectations for a meaningful review process.

Design verification

Design verification confirms that design outputs meet design inputs. Verification is typically conducted through testing, analysis, inspection, or comparison to similar proven designs. Each verification activity must be documented with the verification method, the acceptance criteria, the results, and a conclusion as to whether the design input was met.

A critical point: verification confirms that you built the device to specification. It does not confirm that you built the right device. That is what validation does.

Design validation

Design validation confirms that the device meets user needs and intended uses under actual or simulated use conditions. Validation must be performed on production-equivalent units (not early prototypes), and it must address the full range of users and use environments identified in the design inputs.

For devices involving human use, validation typically includes usability testing conducted in accordance with FDA’s human factors guidance. The validation must be explicitly linked to the design inputs established at the beginning of the design process. An FDA reviewer should be able to see a direct connection between the user needs captured in design inputs and the validation test protocols designed to confirm that those needs are met.

Design transfer

Design transfer is the process of translating the design into production. The DHF must contain evidence that the design was formally transferred to manufacturing, that production processes are capable of producing devices that meet design specifications, and that the Device Master Record was established and reviewed before production began.

Design changes

Every change made to the device design after the initial design transfer must be documented in the DHF through the design change control process. The change record must include the reason for the change, the potential impact on the device’s safety, effectiveness, or regulatory status, the verification and/or validation performed to confirm the change does not create new risks, and the approval of qualified personnel.

Design changes with uncontrolled documentation are among the most frequently cited DHF deficiencies in FDA inspections. When a device undergoes multiple design iterations over its commercial life but the DHF is not updated to reflect those changes, investigators cannot determine whether the device being manufactured is actually the device that was validated.

Risk management integration

Under the QMSR and ISO 13485:2016, risk management is expected to be integrated throughout the design process, not performed as a standalone document at the end. The DHF should contain or reference the risk management file (per ISO 14971), and risk assessment results should be traceable to design inputs, design outputs, and verification/validation activities. The risk register maintained during design development must reflect how identified hazards were addressed through design changes, protective measures, or labeling.

Common DHF failures that generate FDA citations

The patterns that lead to DHF-related observations are consistent across FDA inspection reports and warning letters.

Missing traceability. A DHF where design inputs, outputs, and verification records exist as separate documents with no connecting links fails to demonstrate a controlled design process. The investigator cannot confirm that every design input was addressed by a design output and verified.

Inadequate design inputs. Vague or unverifiable design inputs are a foundational problem because everything downstream relies on them. If the requirements are not specific and measurable, verification cannot confirm they were met, and validation cannot confirm the device meets user needs.

Incomplete design change records. Device modifications made during development or post-market without corresponding design change records create a DHF that does not reflect the actual device. This is particularly problematic for software-containing devices where firmware updates may not have triggered formal change control.

Validation on non-representative units. Performing design validation on pre-production prototypes that differ materially from the production device does not satisfy FDA’s requirement that validation be performed on production-equivalent units.

No connection between risk management and design decisions. A risk management file that exists as a separate document with no visible influence on design inputs, design changes, or validation scope does not demonstrate that risk management was genuinely integrated into the design process.

How Cloudtheapp supports design history file management

Managing a DHF across a multi-year development program, with multiple engineering disciplines, iterative design changes, and evolving regulatory requirements, is genuinely difficult with paper-based or disconnected systems. When verification test results live in one system, design change records in another, and the risk management file in a third, traceability becomes a manual effort that creates inconsistency and audit risk.

Cloudtheapp’s design controls module links design inputs, design outputs, verification records, validation protocols, and design change records within a single quality management environment. The traceability matrix is generated automatically from the linked records, so quality teams spend less time assembling evidence packages and more time doing engineering work. The audit trail captures every record creation, revision, and approval, giving FDA reviewers the complete document history they expect to see.

With 60+ applications covering the full quality and compliance lifecycle for medical device, pharma, and biotech companies, Cloudtheapp supports design control programs from initial product concept through post-market design changes. Schedule a demo to see how the design controls and DHF management features work in practice.

Conclusion

A DHF that passes FDA review is not a collection of documents assembled at the end of development. It is a living record built throughout the design process, where each phase generates documented evidence that is linked to the phases before and after it. The traceability between design inputs, design outputs, verification, and validation is what gives an investigator confidence that the design process was genuinely controlled. Organizations that build traceability into their design process from the first requirements workshop tend to produce DHFs that hold up under scrutiny. Those that try to reconstruct traceability after the device is already in production typically find gaps that are difficult to close without repeating development work.

This post created by and appeared first on Cloudtheapp